SCHEMBL1011752

SCHEMBL1011752

CC(C)(C)OC(=O)N1CCC(=Cc2cccc(Oc3ccc(F)cc3)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR2 O95136 1/20 0.48
CYP3A4 P08684 5/20 0.44
CYP2D6 P10635 5/20 0.44
GPR119 Q8TDV5 2/20 0.43
FAAH O00519 1/20 0.43
GABRA1 P14867 1/20 0.43
ADRA2C P18825 1/20 0.43
CNR1 P21554 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
CNR2 P34972 1/20 0.43
HTR2B P41595 1/20 0.43
TMEM97 Q5BJF2 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
GRM5 P41594 3/20 0.42
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1011241 0.91 ESR2 (0.46) S1PR2CYP3A4CYP2D6GPR119FAAH
SCHEMBL1012311 0.91 ALDH1A1 (0.46) CYP3A4CYP2D6GPR119FAAHGABRA1
SCHEMBL1011421 0.88 FAAH (0.46) CYP3A4CYP2D6GPR119FAAHGABRA1
SCHEMBL27233593 0.87 FAAH (0.42) S1PR2CYP3A4CYP2D6GPR119FAAH
SCHEMBL1009416 0.86 CYP3A4 (0.56) CYP3A4CYP2D6GPR119FAAHGABRA1
SCHEMBL16113858 0.86 GRM5 (0.47) CYP3A4GPR119GRM5MEN1KMT2A
SCHEMBL6396022 0.85 ABCB1 (0.48) GPR119GRM5MAPTMEN1KMT2A
Hydrochloric Acid SCHEMBL4184397 0.84 FAAH (0.47) CYP3A4CYP2D6GPR119FAAHGABRA1
SCHEMBL1010576 0.84 FAAH (0.48) CYP3A4CYP2D6GPR119FAAHGABRA1
SCHEMBL27233589 0.83 GPR119 (0.47) CYP3A4CYP2D6GPR119FAAHGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC S1PR2 705/4885CYP3A4 303/4885CYP2D6 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.